CDSCO

The Central Drugs Standard Control Organisation (CDSCO) has released its monthly drug quality alert for May 2026, identifying 157 drug samples as Not of Standard Quality (NSQ) and 2 drug samples as Spurious following testing by Central and State Drug Testing Laboratories across the country. The findings underscore the importance of continuous post-marketing surveillance to ensure the quality, safety and efficacy of medicines available to patients.

In a significant development in the biosimilar segment, the Subject Expert Committee (SEC) on Dermatology & Allergy has recommended granting permission to M/s Kemwell Biopharma Private Limited to conduct a comparative pharmacokinetic clinical study for its proposed Dupilumab biosimilar, ASP100.

The recommendation was made during the 6th SEC (Dermatology & Allergy) meeting of 2026, held on June 11, 2026, at the CDSCO Headquarters in New Delhi.

AstraZeneca Pharma India has announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan (Enhertu) 100 mg/5 mL, allowing its use in combination with pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer. The approval covers patients whose tumors are classified as HER2-positive through IHC 3+ or ISH+ testing.

Wockhardt has received marketing authorization from India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), for its breakthrough antibiotic ZAYNICH® (Zidebactam/Cefepime). The approval marks a significant milestone for India’s fight against antimicrobial resistance, especially in difficult-to-treat Gram-negative bacterial infections.

Applications are invited from eligible candidates for appointment to the 43 posts of Drugs lnspector (Medical Devices) Gazetted, Non-ministerial, Pay level 8 (Rs.47600-151 100) of 7th CPC in the Central Drugs Standard Control Organisation, Directorate General of Health Services, Ministry of Health & Family Welfare on deputation basis across all the zones/ sub-zones including Head Quarter under the CDSCO.

Post : Drugs Inspector

No of posts : 43

The Central Drugs Standard Control Organisation (CDSCO) has issued a public notice clarifying that cosmetic products cannot be used through injections and are not permitted for treatment purposes under Indian law.

The notice, released by the Directorate General of Health Services under the Ministry of Health and Family Welfare, comes amid rising use of aesthetic and beauty procedures in clinics and salons across the country.